Neurocrine Biosciences (NBIX) is drawing fresh attention after announcing it will present new long term CRENESSITY crinecerfont data in classic congenital adrenal hyperplasia at ENDO 2026 in Chicago.

The CRENESSITY data update comes at a time when momentum in Neurocrine Biosciences’ stock has been strong, with a 30 day share price return of 23.15%, a 27.36% 90 day share price return and a 32.60% 1 year total shareholder return, suggesting that investors are reassessing both growth prospects and risk around its endocrine and neuroscience pipeline alongside recent conference appearances and pre arranged insider stock sales.

If this kind of move has your attention, it can be helpful to see what else the market is rewarding in similar areas. A good place to start is 39 healthcare AI stocks

With Neurocrine Biosciences now carrying a market value of about US$15.6b, US$3.1b in annual revenue and US$668.6m in net income, the key question is whether the current valuation leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 11.4% Undervalued

Against the last close of $165.11, the most followed narrative points to a higher fair value, framing current pricing against long term earnings power assumptions.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.

Want to see what sits behind that earnings story, and why the fair value comes out higher than today’s price? The narrative leans heavily on sustained revenue growth, rising margins and a richer earnings multiple by the end of the decade. Curious which assumptions really move the model and how sensitive that $186.45 fair value is to them?

Result: Fair Value of $186.45 (UNDERVALUED)

However, the story can change quickly if pricing pressure on INGREZZA intensifies or if CRENESSITY and late stage CNS programs fall short of current analyst uptake expectations.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: What Earnings Multiples Are Saying

That 11.4% undervaluation signal from the fair value narrative runs into a different message when you look at the earnings multiple. Neurocrine Biosciences trades on a P/E of 24.8x, which sits above both the US Biotechs industry at 16.4x and its peer group at 21.7x, yet below its own fair ratio of 26.5x that the market could move towards. For you, that mix of relative expensiveness against the sector but a discount to the fair ratio raises a simple question: is this pricing closer to a cushion or a tightrope?

Next Steps

With sentiment looking optimistic, this is a good moment to move quickly, test the numbers yourself and decide if the optimism feels justified. To help you weigh the upside drivers, take a closer look at the 3 key rewards

Looking for more investment ideas?

If Neurocrine Biosciences has you thinking more broadly about opportunities, do not stop here. The next move that fits your approach could be waiting nearby.

• Target stability with companies that prioritise strong finances by using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for potential value by scanning the 47 high quality undervalued stocks before price and fundamentals drift further apart.
• Spot opportunities the crowd may be missing by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.